L-Carnitine Protective Effect in Nephrotoxicity

Inclusion Criteria: * Male or female patients. * Newly diagnosed patients with cancer and with an indication for cisplatin - based chemotherapy. * Age between 18 and 75 years. * No serious cardiopulmonary comorbidity which could impair involvement in the study. * Creatinine clearance value above 50 mL/min/1.73 m². * Patients who will scheduled to receive at least 3 cycles of cisplatin. * Patients with no previous renal diseases (including acute nephropathy, acute and chronic renal failure). Exclusion Criteria: * Pregnancy or lactation. * Metastasis to the central nervous system. * Psychiatric disorders. * Prior treatment with platinum derivatives. * Hypersensitivity to cisplatin, carboplatin or other platinum derivatives. * Patients with active infection or any symptoms of sepsis. * Acute renal failure or renal surgery within the last 3 months. * Patients unfit for cisplatin (patients with impaired renal function, sensorineural hearing loss and cardiomyopathy). * Patients with known history or current treatment with nephrotoxic agents. * Taking other antioxidant supplements such as Vitamins C and E.